Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers cochlear implant systems; replacement sound processors, accessories, and other services; bone conduction systems and replacement sound processors; and recipient support tools. The company also provides Cochlear connected care solutions, such as Cochlear Nucleus SmartNav System; Cochlear Custom Sound Pro Fitting Software; Cochlear Remote Assist; Cochlear Remote Check; and Cochlear Link. It offers its products and services under the Cochlear, Nucleus, Nexa, Osia, and Cochlear Baha brands. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Frequently asked questions
What sector does Cochlear Limited (CHEOF) operate in?
Cochlear Limited belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Cochlear Limited (CHEOF) current stock price?
As of the latest data, Cochlear Limited stock price is $92.00, with a previous close of $92.00.
What is Cochlear Limited (CHEOF) current market capitalization?
Cochlear Limited market cap is approximately 6.02 billion.
What is Cochlear Limited (CHEOF) Earnings Per Share (EPS)?
The trailing EPS is $1.53.
What is Cochlear Limited (CHEOF) Price-to-Earnings (P/E) ratio?
Cochlear Limited current P/E ratio is 60.13.
What is Cochlear Limited (CHEOF) EBITDA?
Cochlear Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 134.41 million.
Does Cochlear Limited (CHEOF) pay dividends?
Yes. Cochlear Limited pays semiannual dividends with an annualized yield of 4.03% and an estimated annual payout of $3.71 per share.
When is the next ex-dividend date for Cochlear Limited (CHEOF)?
The next ex-dividend date is scheduled for March 22, 2027.
What is Cochlear Limited (CHEOF) beta (volatility) score?
Cochlear Limited has a beta of 0.241, indicating lower volatility than the overall market.
